Intravenous administration of a high-dose AAV gene therapy to boost VEGF has shown to increase lifespan in mice. This highlights the importance of maintaining capillary density through angiogenesis, a process crucial for new blood vessel formation. Upregulating VEGF can aid in restoring capillary networks.
A similar gene therapy is being tested in clinical trials for treating coronary artery disease by promoting blood flow to heart tissue. Preliminary findings from the EXACT phase II trial suggest promising results. Enhancing angiogenesis via VEGF upregulation could benefit older individuals.
Gene therapy targeting VEGF to stimulate new blood vessel growth shows potential in treating advanced coronary artery disease (CAD). The EXACT trial results demonstrate safety and efficacy in improving blood flow and reducing angina symptoms in patients with severe CAD.
